| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2022-02-17 |
| タイトル |
|
|
タイトル |
Therapeutic effects of a 186re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| ID登録 |
|
|
ID登録 |
10.24517/00065227 |
|
ID登録タイプ |
JaLC |
| 著者 |
Ogawa, Kazuma
Mukai, Takahiro
Asano, Daigo
Kawashima, Hidekazu
Kinuya, Seigo
Shiba, Kazuhiro
Hashimoto, Kazuyuki
Mori, Hirofumi
Saji, Hideo
|
| 著者別表示 |
小川, 数馬
絹谷, 清剛
柴, 和弘
森, 厚文
|
| 提供者所属 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
金沢大学疾患モデル総合研究センター |
| 書誌情報 |
Journal of Nuclear Medicine
巻 48,
号 1,
p. 122-127,
発行日 2007-01
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0161-5505 |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
2159-662X |
| NCID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA00703684 |
| 出版者 |
|
|
出版者 |
Society of Nuclear Medicine |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Previously, based on the concept of bifunctional radiopharmaceuticals, we developed a highly stable 186Re-mercaptoacetylglycylglycylglycine (MAG3) complex-conjugated bisphosphonate, [[[[(4-hydroxy-4,4-diphosphonobutyl) carbamoylmethyl]carbamoylmethyl] carbamoylmethyl]carbamoylmethanethiolate] oxorhenium(V) (186Re-MAG3-HBP), for the treatment of painful bone metastases. This agent showed a superior biodistribution as a bone-seeking agent in normal mice when compared with 186Re-1-hydroxyethylidene-1,1- diphosphonate (186Re-HEDP). In this study, we evaluated the therapeutic effects of 186Re-MAG3-HBP using an animal model of bone metastasis. Methods: The model was prepared by injecting syngeneic MRMT-1 mammary tumor cells into the left tibia of female Sprague-Dawley rats. 186Re-MAG3-HBP (55.5, 111, or 222 MBq/kg) or 186Re-HEDP (55.5 MBq/kg) was then administered intravenously 21 d later. To evaluate the therapeutic effects and side effects, tumor size and peripheral blood cell counts were determined. Palliation of bone pain was evaluated by a von Frey filament test. Results: In the rats treated with 186Re-HEDP, tumor growth was comparable with that in untreated rats. In contrast, when 186Re-MAG3-HBP was administered, tumor growth was significantly inhibited. Allodynia induced by bone metastasis was attenuated by treatment with 186Re-MAG3-HBP or 186Re-HEDP, but 186Re-MAG3- HBP tended to be more effective. Conclusion: These results indicate that 186Re-MAG3-HBP could be useful as a therapeutic agent for the palliation of metastatic bone pain. Copyright © 2006 by the Society of Nuclear Medicine, Inc. |
| 権利 |
|
|
権利情報 |
Copyright © Society of Nuclear Medicine |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 関連URI |
|
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
http://jnm.snmjournals.org/ |
|
|
関連名称 |
http://jnm.snmjournals.org/ |
| 関連URI |
|
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
https://jnm.snmjournals.org/content/48/1/122 |
|
|
関連名称 |
https://jnm.snmjournals.org/content/48/1/122 |
ME-PR-SHIBA-K-122.pdf (979.4 kB)
.png)
